Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Canakinumab

Arthritis and Rheumatology

Volumn 68, Issue 1, 2016, Pages 218-228

  Grom, Alexei A ^a   Ilowite, Norman T ^b   Pascual, Virginia ^c   Brunner, Hermine I ^a   Martini, Alberto ^d   Lovell, Daniel ^a   Ruperto, Nicolino ^d   Leon, Karolynn ^e   Lheritier, Karine ^e   Abrams, Ken ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d UNIVERSITY OF GENOA   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CORTICOSTEROID; CYCLOSPORIN A; ETOPOSIDE; GANCICLOVIR; IMMUNOGLOBULIN; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; CONVALESCENCE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; EPSTEIN BARR VIRUS INFECTION; FEMALE; GASTROENTERITIS; HISTIOCYTE; HUMAN; HYPERFERRITINEMIA; IMPETIGO; INCIDENCE; INFECTION; LIVER DYSFUNCTION; MACROPHAGE ACTIVATION SYNDROME; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; YOUNG ADULT; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; FACTUAL DATABASE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMANS; INFECTION; MACROPHAGE ACTIVATION SYNDROME; MALE; RISK FACTORS; YOUNG ADULT;

EID: 84952010861     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39407     Document Type: Article

References (54)

1. Schneider R, Laxer RM., Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998; 12: 245-71.
2. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al., Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991-4.
3. Mellins ED, Macubas C, Grom AA., Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-26.
4. Verbsky JW, White AJ., Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
5. Irigoyen PI, Olson J, Hom C, Ilowite NT., Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004; 50 Suppl: S437-8.
6. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
7. De Benedetti F, Martini A., Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25: 203-7.
8. Hadchouel M, Prieur AM, Griscelli C., Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-6.
9. Grom AA., Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? [review]. Arthritis Rheum 2004; 50: 689-98.
10. Sawhney S, Woo P, Murray KJ., Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421-6.
11. Moradinejad MH, Ziaee V., The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr 2011; 63: 459-66.
12. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al., The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 965-71.
13. Behrens EM, Beukelman T, Paessler M, Cron RQ., Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-8.
14. Athreya BH., Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002; 20: 121-3.
15. Filipovich HA., Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin North Am 2002; 22: 281-300.
16. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U., Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-22.
17. Henter JI, Andersson B, Elinder G, Jakobson A, Lubeck PO, Soder O., Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 1996; 27: 21-5.
18. Ravelli A, De Benedetti F, Viola S, Martini A., Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-8.
19. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM., Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285-92.
20. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al., HLH-2004: diagnostic and therapeutic guidelines for hemopagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-31.
21. Coco A, Bundy KW, Marston B, Huggins J, Looney RJ., Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol 2009; 132: 10-8.
22. Schulert GS, Grom AA., Macrophage activation syndrome and cytokine directed therapies. Best Pract Res Clin Rheumatol 2014; 28: 277-92.
23. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al., A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
24. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, et al., Two randomized trials of canakinumab in systemic juvenile arthritis with active systemic features. N Engl J Med 2012; 367: 2396-406.
25. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al., Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
26. De Benedetti F, Brunner HI, Ruperto N, Kenwright, A, Ravelli A, Schneider R, et al., Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.
27. Kahn PJ, Cron RQ., Higher dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 2013; 40: 743-4.
28. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ., Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50: 417-9.
29. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al., Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15: 161-4.
30. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al., Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55.
31. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C., Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-γ-producing lymphocytes and IL-6- and TNF-α-producing macrophages. Blood 2005; 105: 1648-51.
32. Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, et al., Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 2012; 64: 1680-8.
33. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al., for the Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-67.
34. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A., Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
35. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al., Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
36. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al., An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 764-8.
37. Ringold S, Weiss PF, Beukelman T, DeWitt, EM, Ilowite NT, Kimura Y, et al., 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499-512.
38. Ringold S, Weiss PF, Beukelman T, DeWitt, EM, Ilowite NT, Kimura Y, et al., 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) 2013; 65: 1551-63.
39. Schulert GS, Grom AA., Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med 2015; 66: 145-59.
40. DeBenedetti F, Schneider R, Weitzman S, Devlin C, Daimaru K, Yokota S, et al., Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab [abstract]. Pediatr Rheumatol Online J 2014; 12 Suppl 1: P55.
41. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A., Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011; 21: 92-6.
42. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al., Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012; 58: 287-94.
43. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al., Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010; 49: 1645-53.
44. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, et al., Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004; 50: 1935-38.
45. Dinarello CA., Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007; 27: 98-114.
46. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al., Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005; 106: 3483-9.
47. Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM., Interferon-γ mediates anemia but is dispensable for fulminant Toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 2013; 65: 1764-75.
48. Jordan MB, Hildeman D, Kappler J, Marrack P., An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon γ are essential for the disorder. Blood 2004; 104: 735-43.
49. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al., Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford) 2015; 54: 1507-17.
50. Bracaglia C, Caiello I, de Graaf K, D'Ario G, Guilhot F, Ferlin W, et al., Interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA): high levels in patients and a role in a murine MAS model [abstract]. Abstracts of the 21st European Paediatric Rheumatology Congress; 2014 Sep 17-21; Belgrade, Serbia. Pediatric Rheumatology 2014; 12 Suppl 1: O3.
51. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, et al., Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 2011; 118: 5794-8.
52. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al., Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49: 441-9.
53. Zhang M, Behrens EM, Atkinson TP, Shakoory B, Grom AA, Cron RQ., Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep 2014; 16: 439.
54. Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al., Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014: 66: 3486-95.